Quarterly report pursuant to Section 13 or 15(d)

Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) - Changes in Accumulated Other Comprehensive Income (Loss), Net of Tax (Details)

v3.20.4
Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) - Changes in Accumulated Other Comprehensive Income (Loss), Net of Tax (Details) - USD ($)
$ in Thousands
 6 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Balance as of June 30, 2020 attributable to Bio-Techne $ 1,381,192 $ 1,165,589
Balance as of December 31, 2020 attributable to Bio-Techne(3) 1,521,916 1,323,348
AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]    
Balance as of June 30, 2020 attributable to Bio-Techne (13,253) (9,537)
Other comprehensive income (loss) before reclassifications, net of taxes, attributable to Bio-Techne (47) 275
Reclassification from loss on derivatives to interest expense, net of taxes, attributable to Bio-Techne(1) 4,249 [1] 629 [2]
Other comprehensive income (loss), net of tax before reclassifications, attributable to Bio-Techne (47) 275
Balance as of December 31, 2020 attributable to Bio-Techne(3) [3] (9,051) (8,633)
Accumulated Foreign Currency Adjustment Attributable to Parent [Member]    
Balance as of June 30, 2020 attributable to Bio-Techne (83,946) (73,983)
Other comprehensive income (loss) before reclassifications, net of taxes, attributable to Bio-Techne 28,759 4,264
Reclassification from loss on derivatives to interest expense, net of taxes, attributable to Bio-Techne(1) 0 0
Other comprehensive income (loss), net of tax before reclassifications, attributable to Bio-Techne 28,759 4,264
Balance as of December 31, 2020 attributable to Bio-Techne(3) [3] (55,187) (69,719)
Accumulated Other Comprehensive Income (Loss), Derivative Qualifying as Hedge, Excluded Component, Including Portion Attributable to Noncontrolling Interest [Member]    
Balance as of June 30, 2020 attributable to Bio-Techne (97,199) (83,521)
Other comprehensive income (loss) before reclassifications, net of taxes, attributable to Bio-Techne 28,712 4,539
Reclassification from loss on derivatives to interest expense, net of taxes, attributable to Bio-Techne(1) 4,249 [1] 629 [2]
Other comprehensive income (loss), net of tax before reclassifications, attributable to Bio-Techne 28,712 4,539
Balance as of December 31, 2020 attributable to Bio-Techne(3) [3] $ (64,238) $ (78,352)
[1] Gains (losses) on the interest swap are reclassified into interest expense as payments on the derivative agreement are made. The Company reclassified $5,026 to interest expense and $512 to non-operating income relating to variable interest payments that were probable not to occur as further discussed in Note 6 in the six months ended December 31, 2020. The Company also recorded a related tax benefit of $1,289 during the six months ended December 31, 2020.
[2] The Company reclassified ($821) to interest expense and a related tax benefit tax of $192 during the six months ended December 31, 2019.
[3] The Company had deferred tax benefits of $2,886 and $4,058 included in the accumulated other comprehensive income loss as of December 31, 2020 and June 30, 2020, respectively.